2021 U-M Kellogg Eye Center Annual Report

Page 12

WE OFFER MULTIPLE TREATMENT

OPTIONS FOR PATIENTS WITH ANY

COMBINATION OF SEVERE SYMPTOMS.

— Roni Shtein, M.D., M.S.

Roni Shtein, M.D., demonstrates corneal staining technique with Sheila Gilbert, COA

Finding a Personalized Solution for Dry Eye According to the American Academy of Ophthalmology (AAO), approximately 20 million Americans, and nearly 350 million people worldwide, suffer from inadequate lubrication of the eye, or dry eye disease. Many factors can contribute to dry eye. It is a frequent

Serum tears — Eye drops made from the serum of a patient’s

own blood contain growth factors and nutrients shown to be effective in decreasing symptom severity. Kellogg has developed the protocols used by a U-M blood draw station and a local compounding pharmacy to formulate these ‘customized tears.’ A mail order option through an outside vendor is available to patients out of the area.

medication side effect, a comorbidity of some systemic diseases

Scleral contact lenses — Contact lenses scaled to fit over the

and, most commonly, simply a consequence of growing older.

white of the eye can keep moisture in and cushion the surface

It is mildly uncomfortable for some patients, excruciating for

of the eye. Kellogg also offers the Prosthetic Rehabilitation of

others. Yet despite diminishing the quality of life of so many,

the Ocular Surface Ecosystem (PROSE), a customized scleral

dry eye remains, as EyeNet® magazine states, “notoriously

lens that bathes the eye with artificial tears.

underappreciated, misdiagnosed, and undertreated.” In the Cornea Clinic at Kellogg, improving the lives of patients with dry eye disease is a top priority. Patients are frequently referred to Kellogg when the established first-line treatment — lubricating eye drops — falls short. Patients with

10

Some Innovative Treatment Modalities Offered:

Intense pulsed light treatment (IPL) — For dry eye

caused by meibomian gland dysfunction, IPL treatment to the eyelids can reduce inflammation and improve meibomian gland function.

the most complex, hard-to-manage conditions are often seen

Research — The cornea specialists at Kellogg are also involved

by dry eye specialist Roni Shtein, M.D., M.S.

in research to improve treatment of dry eye or chronic symp-

“Ocular surface dryness is at its most acute when it is

toms. For example, Kellogg is currently recruiting patients as

associated with ocular surface damage or scarring, when it

part of a multi-center clinical trial of an eye drop for treating

is accompanied by visual abnormalities or diminished vision,

chronic eye pain or dry eye-like symptoms in a post-surgical

or when it occurs with a component of centralized pain,”

population. The eventual goal of the treatment will be to treat

Dr. Shtein explains. “We offer multiple treatment options for

patients with chronic pain/symptoms, regardless of the underly-

patients with any combination of these severe symptoms.”

ing ocular conditions.


Turn static files into dynamic content formats.

Create a flipbook

Articles inside

Toward a Therapeutic Target for Proliferative Vitreoretinopathy

2min
page 25

State-of-the-Science Microscope Gives Kellogg Researchers New Edge

2min
page 25

Michigan Medicine to Establish Neural Engineering Training Program

2min
page 21

Endocrine Society Award

1min
page 21

Leading on the National Stage

2min
page 15

Marshall Parks Lecture at AAO

1min
page 13

Prioritizing Communication for Patient Safety

2min
page 13

New Faculty Members

3min
page 42

Alumni Highlights

4min
page 39

Recognizing Distinguished Alumni Richard Gutow, M.D., and Gary Gutow, M.D.

6min
pages 36-37

Guarding Photoreceptor Metabolism to Prevent Vision Loss in Inherited Retinal Diseases

2min
page 31

Big Data, Collaboration, and Impact

3min
page 35

A Visionary Legacy

3min
page 33

Eyes on the Future

3min
page 34

Kellogg’s Latest Heed Fellows

3min
page 32

U-M Learners Produce Online Newsletter

3min
page 29

Next-Generation Tools to Treat Abnormal New Ocular Blood Vessels

3min
page 28

Genetically-Modified Occludin Shown to Protect Against Diabetes-Related Vision Loss

2min
page 30

Innovation in Action

3min
page 24

New Pediatric Ophthalmology Fellowship in Ghana

3min
page 27

Kellogg Addresses Technician Shortage with Ongoing Training Program

2min
page 26

Kellogg Researcher Launches First of-its-Kind Study of Health and Aging in Kenya

2min
page 23

A New Regulator of Retinal Angiogenesis Discovered

2min
page 22

Lipid Droplets May Protect Against AMD

2min
page 20

Mapping the Genetic Landscape of Nanophthalmos

2min
page 19

Training Eye Disease Researchers in India

2min
page 18

Kellogg Leads International Team Linking Family’s Symptoms to Rare, Inherited Syndrome

4min
pages 14-15

Clinical Research Update: Patient Perspectives

4min
page 17

Finding New Pathways for the Treatment of Choroideremia

2min
page 16

Finding a Personalized Solution for Dry Eye

3min
page 12

Vitreoretinal Lymphoma: from Symptoms to Diagnosis to Treatment

5min
pages 4-5

In it Together

5min
pages 10-11

Collaborating to Deliver Specialized Care

3min
pages 8-9

Steno North American Fellowship

2min
page 5

The Chair’s Perspective

2min
page 3

Kellogg Offers Multiple Options for Limbal Stem Cell Deficiency

3min
page 7

COVID-19 Transmission Risk in Cornea Transplantation

2min
page 9

NIH-Funded Pilot Program Addresses Disparities in Glaucoma Care

3min
page 6
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.